Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burosumab for Osteomalacia in Adults with XLH
NCT02537431Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Dec 2015
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of burosumab in X-linked hypophosphatemia (XLH), sponsored by Kyowa Kirin. Primary endpoint: Percent Change From Baseline in Osteoid Volume/Bone Volume at 48 weeks. Started Dec 2015; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphatemia (XLH)
Beyond the preview
Go deeper on NCT02537431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537431.